Liquid Chromatography Analyzer Evaluated for Hemoglobinopathy

Blood specimens were obtained from patients whose diabetic control or hemoglobinopathy were being assessed.

The scientist measured HbA2 values with the fully automated Glycohemoglobin analyzer based on HPLC ADAMS A1c HA-8180 on Thalassemia mode and were compared with those obtained with their current method, the established HPLC ADAMSTM A1c HA-8160. Comparison was performed by running 400 samples from healthy subjects, 30 alpha and 80 beta carriers. Hemoglobin was measured on a XN counter. Different common variant hemoglobins were analyzed: HbS, HbC, HbD, HbJ, Hb Lepore, HbSC, Hb E, Hb O, and δβ thalassemia carriers with raised HbF. Twenty samples of heterozygous HbS were measured with capillary electrophoresis in the reference laboratory to discard the spurious increment of HbA2.

The mean difference between HbA2 results of ADAMS A1C HA-8180T and capillary electrophoresis, in samples of heterozygous HbS, was 0.2 %. The hematologist found an ample gap between healthy persons and carriers. A potential bias is that they have not included carriers of mutations producing borderline values of HbA2, which was absent in the area, and this fact must be considered in regions with high prevalence of those patients. The author concluded that the ADAMS A1c HA-8180T provided a rapid and reliable separation of HbA2. The measurement is accurate and reproducible, which is needed because of the slight difference between normal and pathological values. The gap in HbA2 values between normal subjects and β-thalassemia carriers makes this an appropriate method for rapid screening for carriers. The study was published in the December 2016 issue of the International Journal of Laboratory Hematology.